Molecular imaging of brain amyloid in mild cognitive impairment and Alzheimer's disease
Paul M Matthews
Correspondence GSK Clinical Imaging Centre, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
Email paul.m.matthews@gsk.com
This article has no abstract so we have provided the first paragraph of the full text.
A proportion of people with the recently defined syndrome of MCI are at high risk of developing AD over the short term, with about 12% of those with the amnestic form of MCI showing progression to AD each year.1 The current study demonstrates that PET using the 
-amyloid-binding radioligand FDDNP can distinguish people with MCI from patients with AD on the basis of brain amyloid load. It indicates that the transition from MCI to AD is associated with brain amyloid accumulation.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.